ClinicalTrials.gg
WithdrawnNCT05252598MELOUpdated Mar 20, 2023

Mood and Cognitive Effects of Psilocybin in Healthy Participants

An Early Phase 1 interventional study of Psilocybin and Inonotus Obliquus Whole Extract in Mood Disturbance, Mood Change and Sleep Disturbance, sponsored by Optimi Health Corporation. Withdrawn. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-20.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Optimi Health Corporation · Early Phase 1, Interventional, and Treatment

Why this study was withdrawn
The sponsor no longer wishes to pursue the methods outlined in the protocol.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects.

Read the detailed description

Psilocybin is a natural psychoactive alkaloid component of more than 200 species of naturally growing mushrooms that can be found throughout the world. Psilocybin use as a ceremonious ritual has been well documented in ancient Aztec and Mesoamerican history. Psilocybin was chemically isolated and synthesized in the 1950s by American scientists, who found that mushroom varieties offered varying ranges of natural psilocybin (from 0.2-1% of dry weight). The psychological benefits of psilocybin are well-documented, as are the safety profile, low toxicity, and significant lack of abuse or overdose potential in comparison to other scheduled and non-scheduled drug, including alcohol. Many clinical studies demonstrate the benefit of psilocybin on feelings of depression, mood, and overall feelings of well-being, particularly at higher doses greater than 25mg. At these doses, hallucinations and psychedelic effects also occur. A growing body of evidence suggests that extremely low doses, or microdoses, may offer similar psychological benefits to individuals without any hallucinogenic effect that may impair daily function. The purpose of this study is to examine an optimal small/microdose of psilocybin, taken orally, that may provide such benefits.

Optimi,is committed to providing MELOCIN, an oral, pharmaceutical grade, but naturally derived, mushroom powder (Psilocybe cubensis), containing a specific dose of psilocybin and a controlled range of other natural compounds and excipients within the formulation. Clinical studies will inform the desired low to very low psilocybin dosing range for specific indications which do not elicit any psychedelic effects but are correlated to specific mood and cognition-related enhancements or improvements in otherwise healthy individuals.

Primary objective: To assess the safety and tolerability of varying low doses and microdoses of Optimi psilocybin-containing mushroom powder in healthy humans.

Secondary objective: To assess the magnitude of effects of varying low doses and microdoses of Optimi psilocybin-containing mushroom powder on general mood, physiological responses, cognitive performance, focus, and feelings of anxiety.

Methodology: Double-blind, randomized, placebo-controlled trial examining effects of six oral doses of MELOCIN, a psilocybin-containing Psilocybe cubensis mushroom powder, with 0 (placebo), 1, 2, 5, 8 and 10mg of psilocybin, administered on six separate test days in a randomized fashion. Participants will be randomized to the order that doses are administered. Study days will be scheduled 6-9 days apart to avoid any carry-over effects of a previous dose. Each study day will require ingestion of 10 capsules, which will be a combination of placebo and Psilocybe cubensis powder containing the prescribed daily dose. On the placebo study day, participants will digest 9 placebo capsules and one Chaga mushroom (non-active, non-hallucinogenic) capsule such that the mushroom after-taste commonly present with hallucinogenic magic mushrooms is mimicked and still present to preserve the blinding of the study dosing regimen.

Participants will be scheduled for 7 total weekly visits (6 dosing days, 1 follow up/close out visit) at the study clinic, each estimated to be 8-9 hours in duration. At each weekly study visit, participants will be continuously monitored and asked to complete cognitive, mood, and other psychological questionnaires and provide minimal blood work at 80-105 mins, 2.5 hrs, 5 hrs, and 7.5hrs post-drug administration in order to monitor the physiological and psychological effects of the dose provided that day. At the follow-up visit, final questionnaires will be completed and qualitative feedback on the experience will be collected

02

Conditions studied

  • Mood Disturbance
  • Mood Change
  • Sleep Disturbance
  • Drug Effect
  • Psychedelic Experiences
  • Health, Subjective
  • Psilocin Toxicity
  • Psilocybin Toxicity
  • Psilocybin Causing Adverse Effects in Therapeutic Use
  • Anxiety

Browse trials for

Keywords

  • Psilocybin
  • Magic Mushrooms
  • Microdose
  • Mood
  • Sleep
  • Cognition
03

In context

Anxiety Disorders Unverified

7,220 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

Browse Anxiety Disorders studies →

Lead sponsor

This is the only study on the registry with Optimi Health Corporation as lead sponsor.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy volunteers
  2. Between the age of 18 and 50 years of age
  3. Good physical health as determined by medical history, medication history, blood and urinalysis work up
  4. Willing to provide informed written consent
  5. Able to complete self-assessment questionnaires provided in English
  6. Agree to refrain from using any psychoactive drugs, including alcohol, marijuana, or nicotine, at least 24 hours prior to each study visit
  7. Agree to refrain from using any non-prescription medication at least 24 hours prior to each study visit

Exclusion criteria

Exclusion Criteria:

  1. Unable to complete self-assessment questionnaires in English
  2. Reported history of drug abuse or addiction
  3. History of any neurological, cardiovascular, or psychiatric disorders or conditions.
  4. History, family history in first degree (blood) relatives, or current screening symptoms (as determined by positive mini-international neuropsychiatric interview (MINI) questionnaire) of psychiatric illness (including depression, anxiety disorder, post-partum depression, bipolar disorder, schizophrenia).
  5. History of insulin-dependent diabetes mellitus
  6. Epilepsy with history of seizures
  7. Female participants who are pregnant or nursing
  8. Prescribed medications with centrally-active serotonergic or gamma-aminobutyric acid (GABA)-receptor interactions, such as monoamine oxidase inhibitors (MAOI) antidepressants, serotonin-inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), or neurosteroids
  9. Pacemaker or implanted cardiac defibrillator
  10. Previous head trauma or concussion history
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo Arm

    9 placebo pills and 1 non-hallucinogenic Chaga (Inonotus obliquus) mushroom powder capsule to mimic the after-taste of active Psilocybin pills (Psilocybe cubensis)

    Drug: Inonotus Obliquus Whole Extract

  • Experimental
    1mg Psilocybin Arm

    9 placebo pills and 1 capsule containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 1mg of psilocybin

    Drug: Psilocybin

  • Experimental
    2mg Psilocybin Arm

    8 placebo pills and 2 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 2mg of psilocybin

    Drug: Psilocybin

  • Experimental
    5mg Psilocybin Arm

    5 placebo pills and 5 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 5mg of psilocybin

    Drug: Psilocybin

  • Experimental
    8mg Psilocybin Arm

    2 placebo pills and 8 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 8mg of psilocybin

    Drug: Psilocybin

  • Experimental
    10mg Psilocybin Arm

    0 placebo pills and 10 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 10mg of psilocybin

    Drug: Psilocybin

Interventions

  • 1mg encapsulated psilocybin

    Also known as: Melocin

  • DrugInonotus Obliquus Whole Extract

    1mg encapsulated chaga mushroom

    Also known as: Chaga

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Collection of data from participants regarding adverse events experience during or after administration of the study drug.

    Time frame: Up to 96 hours post-drug administration

  2. Tolerability of doses with regard to reported hallucinogenic or unpleasant effects (Altered States of Consciousness Scale (5D-ASC), self-reported experience)

    Assessment of hallucinogenic effects or unpleasant side effects assessed using the validated 5D-ASC questionnaire

    Time frame: Up to 96 hours post-drug administration

Secondary outcomes

  1. Assessments of physiological effects of psilocybin capsules

    Use of validated questionnaires to assess drug-effects on mood, sleep, memory, cognition, anxiety and depression

    Time frame: Up to 96 hours post-drug administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — There is no plan to share data at this time.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2023; primary completion for Aug 2023, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 23, 2022
StartEst.
Jan 2023
Primary completionEst.
Aug 2023
CompletionEst.
Dec 2023
Last update
Mar 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05252598
Lead sponsor
Optimi Health Corporation
Responsible party
Sponsor
First posted
Feb 23, 2022
Start date
Jan 2023 (estimated)
Primary completion
Aug 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Mar 20, 2023

Study contacts

Valerie Taylor, MD/PhD
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion